Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KALV Stock Forecast 2026-2027
$27.00
Current Price
$1.44B
Market Cap
Buy 0
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to KALV Price Targets
0.0%
To High Target of $27.00
0.0%
To Median Target of $27.00
0.0%
To Low Target of $27.00
KALV Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+68.6%
1 Year Change
+67.2%
Year-to-Date Change
0.0%
From 52W High of $27.00
+174.7%
From 52W Low of $9.83
📊 TOP ANALYST CALLS
Did KALV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if KalVista is one of their latest high-conviction picks.
Latest KALV Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, KALV has a neutral consensus with a median price target of $27.00 (ranging from $27.00 to $27.00). The overall analyst rating is Buy (6.0/10). Currently trading at $27.00, the median forecast implies a 0.0% downside. This outlook is supported by 0 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew S. Fein at HC Wainwright & Co., projecting a 0.0% downside. Conversely, the most conservative target is provided by Andrew S. Fein at HC Wainwright & Co., suggesting a 0.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KALV Analyst Ratings
0
Buy
5
Hold
0
Sell
KALV Price Target Range
Low
$27.00
Average
$27.00
High
$27.00
Current: $27.00
Latest KALV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KALV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | Andrew S. Fein | Neutral | Downgrade | $27.00 |
| Apr 30, 2026 | Needham | Serge Belanger | Hold | Downgrade | $N/A |
| Mar 26, 2026 | Stifel | Buy | Maintains | $N/A | |
| Mar 26, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Mar 25, 2026 | Needham | Buy | Maintains | $N/A | |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 9, 2026 | Needham | Buy | Maintains | $N/A | |
| Jan 6, 2026 | Needham | Buy | Maintains | $N/A | |
| Dec 4, 2025 | Needham | Buy | Reiterates | $N/A | |
| Nov 11, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Sep 12, 2025 | Needham | Buy | Reiterates | $N/A | |
| Sep 12, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jul 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 8, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jul 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 7, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Apr 8, 2025 | Needham | Buy | Reiterates | $N/A | |
| Mar 26, 2025 | Needham | Buy | Reiterates | $N/A | |
| Mar 26, 2025 | Citizens Capital Markets | Market Outperform | Reiterates | $N/A | |
| Mar 26, 2025 | Jones Trading | Buy | Maintains | $N/A |
KalVista Pharmaceuticals Inc. (KALV) Competitors
The following stocks are similar to KalVista based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
KalVista Pharmaceuticals Inc. (KALV) Financial Data
KalVista Pharmaceuticals Inc. has a market capitalization of $1.44B with a P/E ratio of -7.3x. The company generates $114.48M in trailing twelve-month revenue with a -118.7% profit margin.
Revenue growth is +198.4% quarter-over-quarter, while maintaining an operating margin of -57.4% and return on equity of +6,766.7%.
Valuation Metrics
Market Cap
$1.44B
Enterprise Value
$1.44B
P/E Ratio
-7.3x
PEG Ratio
0.1x
Price/Sales
12.6x
Growth & Margins
Revenue Growth (YoY)
+198.4%
Gross Margin
+92.4%
Operating Margin
-57.4%
Net Margin
-118.7%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+19.8%
Current Ratio
5.2x
Debt/Equity
-14.5x
ROE
+6,766.7%
ROA
-54.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
KalVista Pharmaceuticals Inc. (KALV) Business Model
About KalVista Pharmaceuticals Inc.
What They Do
Develops treatments for hereditary angioedema.
Business Model
KalVista Pharmaceuticals generates revenue through the discovery, development, and commercialization of small molecule protease inhibitors, specifically targeting hereditary angioedema (HAE). The company's lead product, EKTERLY, is an FDA-approved oral medication that addresses acute HAE attacks, providing an alternative to traditional injectable therapies. Additionally, they are working on innovative formulations to enhance patient access and adherence, including a pediatric version of their treatment.
Additional Information
KalVista operates in the rare disease sector and focuses on non-invasive, patient-centric solutions to improve treatment satisfaction. With several regulatory approvals and partnerships aimed at international expansion, the company is positioned to play a significant role in enhancing the management of HAE through oral therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
275
CEO
Mr. Benjamin L. Palleiko
Country
United States
IPO Year
2015
Website
www.kalvista.comKalVista Pharmaceuticals Inc. (KALV) Latest News & Analysis
Latest News
Quick Summary
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, enhancing its Rare Diseases business unit focused on therapies for rare conditions.
Why It Matters
Chiesi's acquisition of KalVista enhances its Rare Diseases portfolio, potentially driving growth and innovation, which could positively impact stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings prospects, which may lead to a stock price increase.
Why It Matters
KalVista's Zacks Rank #2 upgrade signals increased confidence in its earnings potential, likely boosting investor sentiment and driving the stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
KalVista Pharmaceuticals presented new data on the challenges of injectable on-demand treatments for children with hereditary angioedema at recent conferences, emphasizing unmet needs in this demographic.
Why It Matters
KalVista's data on the challenges of injectable treatments for children with HAE signals potential market opportunities for innovative therapies, impacting future revenue and investment prospects.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
KalVista Pharmaceuticals is being sold to Chiesi Group for $27.00 per share. An investigation is underway to assess the fairness of the transaction for shareholders.
Why It Matters
The investigation into KalVista Pharmaceuticals' sale could impact share value if shareholders perceive the offer as inadequate or if legal issues arise, affecting investor confidence and potential returns.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Chiesi Group is set to acquire KalVista Pharmaceuticals in an all-cash deal worth approximately $1.9 billion, according to a joint statement from both companies.
Why It Matters
The acquisition indicates Chiesi's expansion strategy and potential growth in the U.S. market, impacting both companies' valuations and market positions.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Chiesi will acquire KalVista Pharmaceuticals for approximately $1.9 billion to expand its portfolio in rare disease treatments.
Why It Matters
Chiesi's $1.9 billion acquisition of KalVista enhances its rare disease portfolio, potentially increasing future revenue and market presence, influencing investor sentiment and stock performance.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About KALV Stock
What is KalVista Pharmaceuticals Inc.'s (KALV) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, KalVista Pharmaceuticals Inc. (KALV) has a median price target of $27.00. The highest price target is $27.00 and the lowest is $27.00.
Is KALV stock a good investment in 2027?
According to current analyst ratings, KALV has 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KALV stock?
Wall Street analysts predict KALV stock could reach $27.00 in the next 12 months. This represents a 0.0% decrease from the current price of $27.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is KalVista Pharmaceuticals Inc.'s business model?
KalVista Pharmaceuticals generates revenue through the discovery, development, and commercialization of small molecule protease inhibitors, specifically targeting hereditary angioedema (HAE). The company's lead product, EKTERLY, is an FDA-approved oral medication that addresses acute HAE attacks, providing an alternative to traditional injectable therapies. Additionally, they are working on innovative formulations to enhance patient access and adherence, including a pediatric version of their treatment.
What is the highest forecasted price for KALV KalVista Pharmaceuticals Inc.?
The highest price target for KALV is $27.00 from Andrew S. Fein at HC Wainwright & Co., which represents a 0.0% decrease from the current price of $27.00.
What is the lowest forecasted price for KALV KalVista Pharmaceuticals Inc.?
The lowest price target for KALV is $27.00 from Andrew S. Fein at HC Wainwright & Co., which represents a 0.0% decrease from the current price of $27.00.
What is the overall KALV consensus from analysts for KalVista Pharmaceuticals Inc.?
The overall analyst consensus for KALV is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are KALV stock price projections?
Stock price projections, including those for KalVista Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 8:34 AM UTC